Myriad Defends Policy of Urging Docs to Genetically Counsel BRACAnalysis Customers
February 10, 2010
Myriad Defends Policy of Urging Docs to Genetically Counsel BRACAnalysis Customers
Responding to an HHS committee's request for comment on its educational and marketing practices, Myriad maintained that urging doctors to conduct genetic counseling in house instead of referring patients to a genetic counselor is legally sound, follows professional medical societies' standards, and accommodates the shortage of cancer genetics professionals.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 3, 2010 / Pharmacogenomics Reporter - Myriad Updates Investors on Companion Dx Deals, EU Expansion, and Capturing Asymptomatic Market
March 10, 2010 / Pharmacogenomics Reporter - Myriad Assures Investors of Strong Patent Position Despite ACLU Anti-Gene Patenting Lawsuit
March 10, 2010 / Pharmacogenomics Reporter - SCOTUS Justices Struggle to Draw Line between Isolated DNA, cDNA in Gene Patent Hearing
April 17, 2013 / Pharmacogenomics Reporter - GenomeWeb Feature: Regardless of Gene Patent Challenges, Myriad Faces Shifting Competitive Landscape
April 17, 2013 / Pharmacogenomics Reporter